Digital Measures for Clinical Trial Endpoints in Huntington's Disease

NCT07010705 | Recruiting FDA Device

• 2 other identifiers: STUDY000101591U01FD008429-01
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life. The study may be extended to 3 years to include yearly visits.

Conditions

Huntington Disease; Healthy

Keywords

Huntington Disease

Outcome Measures

Primary Outcomes (6)

• Inter-Method Reliability of Total Time in Chorea (Trunk-Worn vs. Wrist-Worn Device)

  Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants.

  1 week

• Known Group Validity of Total Time in Chorea (Trunk-Worn Device)

  Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants.

  1 week

• Known Group Validity of Total Time in Chorea (Wrist-Worn Device)

  Total time in chorea is calculated by summing the duration of all bouts of detected chorea throughout each day and then summed across the week (normalized to wear time). The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants.

  2 weeks

• Inter-Method Reliability of Stride Time Variability (Trunk-Worn vs. Wrist-Worn Device)

  Stride time variability is defined as the coefficient of variation of stride time, with the median value calculated across all walking bouts lasting at least 10 seconds. The outcome will assess the agreement between trunk-worn and wrist-worn devices among HD and control participants.

  1 week

• Known Group Validity of Stride Time Variability (Trunk-Worn Device)

  Stride time variability is defined as the coefficient of variation of stride time, with the median value calculated across all walking bouts lasting at least 10 seconds. The outcome will assess the ability of the trunk-worn device to differentiate between HD and control participants.

  1 week

• Known Group Validity of Stride Time Variability (Wrist-Worn Device)

  Stride time variability is defined as the coefficient of variation of stride time, with the median value calculated across all walking bouts lasting at least 10 seconds. The outcome will assess the ability of the wrist-worn device to differentiate between HD and control participants.

  2 weeks

Study Arms (3)

20 HD-ISS Stage 2

(CAG ≥ 40 and sign/symptom of HD) with or without a support person or family member

Device: ActiGraph LEAP; Device: Axivity AX6

20 HD-ISS mild or moderate Stage 3

(CAG ≥40 and sign symptom and functional impact) with or without a support person or family member

Device: ActiGraph LEAP; Device: Axivity AX6

20 Healthy controls

age and sex-matched

Device: ActiGraph LEAP; Device: Axivity AX6

Interventions

ActiGraph LEAP DEVICE

The ActiGraph LEAP has received 510(k) clearance from the US FDA and offers extensive sensor collections, providing continuous digital measures of activity, sleep, mobility, and additional vital signs, including heart rate and variability, oxygen saturation, and skin temperature, in a single fit-for-purpose device.

20 HD-ISS Stage 2; 20 HD-ISS mild or moderate Stage 3; 20 Healthy controls

Axivity AX6 DEVICE

The Axivity AX6 is a data logger capable of recording raw data from a suite of integrated sensors. It features a state of the art 6-Axis movement sensor measuring linear acceleration and angular velocity at high precision. All sensor locations and Orientations are identical to the AX3 for maximum compatibility. All data is stored in its raw, unaltered format on the embedded flash memory.

20 HD-ISS Stage 2; 20 HD-ISS mild or moderate Stage 3; 20 Healthy controls

Eligibility Criteria

• Age: 25 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study will enroll 60 participants: 20 HD-ISS Stage 2 (CAG ≥ 40 and sign/symptom of HD) with or without a support person or family member; 20 HD-ISS mild or moderate Stage 3 (CAG ≥ 40 and sign symptom and functional impact) with or without a support person or family member; and 20 controls (age and sex-matched). Participants will not be excluded based on ethnicity, and no subpopulations will be excluded from this study. We will exert specific efforts to ensure the inclusion of minorities, including the Black and Hispanic populations

You may qualify if:

• Age of 25-65 years.
• Genetically confirmed HD with CAG \>= 40 (HD-ISS Stage 2 or mild/moderate Stage 3)
• English speaking.
• Age of 25-65 years.
• English speaking.
• Self-identified support person or family member of the enrolled participants with HD.
• years or older
• English speaking.

You may not qualify if:

• Diagnosis of juvenile-onset HD.
• History of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe
• Traumatic Brain Injury.
• Use of an assistive device for ambulation.
• Montreal Cognitive Assessment (MoCA) score of 18 or lower
• Acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic,
• cardiovascular or psychiatric disease.
• Pregnancy
• Cannot be enrolled into a blinded intervention trial at Baseline

Sponsors & Collaborators

• University of Rochester: lead
• Food and Drug Administration (FDA): collaborator

Study Sites (1)

University of Rochester Medical Center

Rochester, New York, 14642, United States

RECRUITING

MeSH Terms

Conditions

Huntington Disease

Condition Hierarchy (Ancestors)

Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Dementia; Chorea; Dyskinesias; Movement Disorders; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Central Study Contacts

Sugitha Maheswaran, BS

CONTACT

5857040344; Sugi_maheswaran@urmc.rochester.edu

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor - Department of Neurology

Study Record Dates

• First Submitted: May 30, 2025
• First Posted: June 8, 2025
• Study Start: June 20, 2025
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: January 27, 2026

Record last verified: 2025-05

Locations

US (1)